Jun 12, 2019
Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia andSmall Lymphocytic Lymphoma
Jun 04, 2019
Biosight Receives Orphan Drug Designation From the FDA for BST-236 for the Treatment of Acute Myeloid Leukemia
Jun 03, 2019
IMBRUVICA® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)
May 30, 2019
Sysmex Inostics OncoBEAM(TM)-EGFR Digital PCR Liquid Biopsy Demonstrates Two-fold Higher Detection of p.T790M Mutations in 183 NSCLC Patients in Comparison Study
May 29, 2019
Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809
May 28, 2019
Bio-Techne's New Exosome-Based Liquid Biopsies Helping To Advance Personalized Care In Lung Cancer Diagnostics
May 20, 2019
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Apr 24, 2019
Chronic Lymphocytic Leukemia Market (CLL) - Epidemiology, 7 MM Insight, Diagnosis and Treatment Patterns and Forecast to 2028
Feb 26, 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Feb 14, 2019
Ascentage Pharma Appoints Jeff Kmetz as Chief Business Officer
Jan 28, 2019
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Dec 03, 2018
IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dec 02, 2018
IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date
Nov 28, 2018
XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Nov 26, 2018
Two Posters on DB102 (Enzastaurin) Presented at the American Society of Hematology Annual Meeting
Nov 19, 2018
Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting
Nov 13, 2018
Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium
Nov 06, 2018
Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update
Oct 30, 2018
Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019
Oct 18, 2018
Sysmex Inostics' OncoBEAM(TM) Platform Demonstrates Superior Detection of Clinically-relevant Mutations for Therapy Selection and Molecular Monitoring for Lung and Colon Cancers